JP2010511730A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010511730A5 JP2010511730A5 JP2009540453A JP2009540453A JP2010511730A5 JP 2010511730 A5 JP2010511730 A5 JP 2010511730A5 JP 2009540453 A JP2009540453 A JP 2009540453A JP 2009540453 A JP2009540453 A JP 2009540453A JP 2010511730 A5 JP2010511730 A5 JP 2010511730A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- composition
- progestagen
- concentration
- testosterone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 158
- WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 claims description 79
- 239000000583 progesterone congener Substances 0.000 claims description 79
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 74
- 229960003604 testosterone Drugs 0.000 claims description 39
- 239000003937 drug carrier Substances 0.000 claims description 37
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 32
- 229960003387 progesterone Drugs 0.000 claims description 16
- 239000000186 progesterone Substances 0.000 claims description 16
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 11
- 206010013774 Dry eye Diseases 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 8
- 210000000744 eyelid Anatomy 0.000 claims description 6
- 238000000034 method Methods 0.000 description 89
- -1 testosterone ester Chemical class 0.000 description 24
- NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 8
- 229960004719 nandrolone Drugs 0.000 description 8
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 4
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 4
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 4
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 4
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 4
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 4
- QSLJIVKCVHQPLV-PEMPUTJUSA-N Oxandrin Chemical compound C([C@@H]1CC2)C(=O)OC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 QSLJIVKCVHQPLV-PEMPUTJUSA-N 0.000 description 4
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 4
- 229960000978 cyproterone acetate Drugs 0.000 description 4
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 4
- 229960000766 danazol Drugs 0.000 description 4
- 229940003092 decanoic acid Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 4
- 229960004039 finasteride Drugs 0.000 description 4
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 4
- 229960001751 fluoxymesterone Drugs 0.000 description 4
- 239000003906 humectant Substances 0.000 description 4
- 150000002596 lactones Chemical class 0.000 description 4
- 229960004400 levonorgestrel Drugs 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 4
- 229960002985 medroxyprogesterone acetate Drugs 0.000 description 4
- 229960004296 megestrol acetate Drugs 0.000 description 4
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 4
- 229960001566 methyltestosterone Drugs 0.000 description 4
- 229940053934 norethindrone Drugs 0.000 description 4
- 229960001652 norethindrone acetate Drugs 0.000 description 4
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 229960000464 oxandrolone Drugs 0.000 description 4
- ICMWWNHDUZJFDW-DHODBPELSA-N oxymetholone Chemical compound C([C@@H]1CC2)C(=O)\C(=C/O)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 ICMWWNHDUZJFDW-DHODBPELSA-N 0.000 description 4
- 229960005244 oxymetholone Drugs 0.000 description 4
- ICMWWNHDUZJFDW-UHFFFAOYSA-N oxymetholone Natural products C1CC2CC(=O)C(=CO)CC2(C)C2C1C1CCC(C)(O)C1(C)CC2 ICMWWNHDUZJFDW-UHFFFAOYSA-N 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 150000003146 progesterones Chemical class 0.000 description 4
- 229960000912 stanozolol Drugs 0.000 description 4
- 230000000475 sunscreen effect Effects 0.000 description 4
- 239000000516 sunscreening agent Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- 230000001548 androgenic effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/634,347 US20080132475A1 (en) | 2006-12-05 | 2006-12-05 | Treatment for dry eye |
| PCT/US2007/086517 WO2008070728A2 (en) | 2006-12-05 | 2007-12-05 | Treatment for dry eye using testosterone and progestagen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010511730A JP2010511730A (ja) | 2010-04-15 |
| JP2010511730A5 true JP2010511730A5 (https=) | 2012-01-05 |
Family
ID=39476533
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540451A Pending JP2010511729A (ja) | 2006-12-05 | 2007-12-05 | ドライアイのための処置 |
| JP2009540453A Pending JP2010511730A (ja) | 2006-12-05 | 2007-12-05 | テストステロンおよびプロゲスターゲンを用いたドライアイのための処置 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009540451A Pending JP2010511729A (ja) | 2006-12-05 | 2007-12-05 | ドライアイのための処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20080132475A1 (https=) |
| EP (2) | EP2101785A4 (https=) |
| JP (2) | JP2010511729A (https=) |
| KR (2) | KR20090104814A (https=) |
| CN (2) | CN101636165A (https=) |
| AU (1) | AU2009202711A1 (https=) |
| BR (2) | BRPI0720172A2 (https=) |
| CA (2) | CA2671698A1 (https=) |
| EA (2) | EA200900663A1 (https=) |
| IL (1) | IL199094A0 (https=) |
| MX (2) | MX2009005993A (https=) |
| WO (2) | WO2008070728A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10105441B2 (en) * | 2007-08-16 | 2018-10-23 | The Schepens Eye Research Institute, Inc. | Method for inhibiting or reducing dry eye disease by IL-1Ra |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
| EP2320912B1 (en) * | 2008-08-05 | 2015-01-14 | University College Cork-National University of Ireland, Cork | Treatment of retinal degeneration |
| UA114705C2 (uk) * | 2011-01-26 | 2017-07-25 | Аллерган, Інк. | Андрогенна композиція для лікування офтальмологічного захворювання |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| PT2877184T (pt) * | 2012-07-27 | 2019-12-02 | Glia Llc | Composições e tratamento para doenças e distúrbios oculares |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| ES2649730T3 (es) * | 2013-03-15 | 2018-01-15 | Glia Llc | Distribución craneal de compuestos farmacéuticos |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| RU2016141135A (ru) | 2014-07-29 | 2018-08-28 | Терапьютиксмд, Инк. | Трансдермальный крем |
| SG10202011669PA (en) * | 2014-10-20 | 2020-12-30 | Oyster Point Pharma Inc | Methods of treating ocular conditions |
| WO2016159350A1 (ja) * | 2015-04-03 | 2016-10-06 | 参天製薬株式会社 | ナンドロロンまたはそのエステル、メテノロンまたはそのエステルを有効成分とするドライアイ治療剤 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| CN110072523A (zh) | 2016-09-07 | 2019-07-30 | 格利亚有限责任公司 | 通过脑神经的药理皮肤激活来治疗与神经退行性病症相关的症状 |
| TW202131927A (zh) * | 2019-11-13 | 2021-09-01 | 美商葛莉亞有限責任公司 | 睾固酮組合物 |
| WO2023107796A1 (en) * | 2021-12-11 | 2023-06-15 | The Regents Of The University Of California | Ophthalmic formulations for macular degeneration |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2861920A (en) * | 1954-05-04 | 1958-11-25 | Upjohn Co | Therapeutic suspensions of steroids containing pvp and/or pva |
| JPS59184135A (ja) * | 1983-04-04 | 1984-10-19 | Teijin Ltd | グリセリンピログルタミン酸エステル類を含有する医薬品組成物 |
| US4617299A (en) * | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
| DE3514724A1 (de) * | 1985-04-24 | 1986-10-30 | Albin F. Dr. 4200 Oberhausen Jereb | Salbe zur verbeugung und behandlung von augen- und hauterkrankungen |
| US4914088A (en) * | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
| US5041434A (en) * | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| USRE34578E (en) * | 1990-05-07 | 1994-04-05 | Lubkin; Virginia | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
| ZA912797B (en) * | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| US5958912A (en) * | 1992-04-21 | 1999-09-28 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β |
| CA2133966C (en) * | 1992-04-21 | 1997-09-09 | David A. Sullivan | Ocular androgen therapy in sjogren's syndrome |
| US6107289A (en) * | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
| US5688765A (en) * | 1992-04-21 | 1997-11-18 | The Schepens Eye Research Institute, Inc. | Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β |
| US5366739A (en) * | 1992-08-06 | 1994-11-22 | Deo Corporation | Method of ophthalmic drug delivery |
| EP0656779B1 (en) * | 1992-08-28 | 2000-04-12 | Pharmos Corporation | Submicron emulsions as ocular drug delivery vehicles |
| WO1997020578A1 (en) * | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
| EP1806131A3 (en) * | 1996-07-22 | 2007-08-01 | Renovo Limited | Use of sex steroid function modulators to treat wounds and fibrotic disorders |
| WO1998037871A1 (en) * | 1997-02-28 | 1998-09-03 | Minnesota Mining And Manufacturing Company | Transdermal device for the delivery of testosterone |
| US5869090A (en) * | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
| FR2774587B1 (fr) * | 1998-02-09 | 2000-03-10 | Oreal | Utilisation d'une microdispersion de cire dans une composition cosmetique ou dermatologique |
| US6348210B1 (en) * | 1998-11-13 | 2002-02-19 | Alza Corporation | Methods for transdermal drug administration |
| US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| TR200200406T2 (tr) * | 1999-06-11 | 2002-06-21 | Watson Pharmaceuticals, Inc. | Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması |
| US6569903B2 (en) * | 1999-12-07 | 2003-05-27 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic compositions |
| US6630175B1 (en) * | 2000-06-29 | 2003-10-07 | Johnson & Johnson Consumer Companies, Inc. | Method of reducing eye irritation |
| US6743448B2 (en) * | 2000-12-11 | 2004-06-01 | Abraham H. Kryger | Topical testosterone formulations and associated methods |
| US6659985B2 (en) * | 2002-01-30 | 2003-12-09 | Southern College Of Optometry | Method to use transdermal administration of androgens to the adnexa of the eye |
| WO2004045510A2 (en) * | 2002-11-15 | 2004-06-03 | Panaseca, Inc. | Methods and compositions for alleviating dry eyes |
| US20060111318A1 (en) * | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
| US6984628B2 (en) * | 2003-07-15 | 2006-01-10 | Allergan, Inc. | Ophthalmic compositions comprising trefoil factor family peptides |
| US7960350B2 (en) * | 2003-10-24 | 2011-06-14 | Ader Enterprises, Inc. | Composition and method for the treatment of eye disease |
| US20050202097A1 (en) * | 2004-03-12 | 2005-09-15 | Melbj Holdings, Llc, Florida | Lubricant for the ocular surface |
| US20050234018A1 (en) * | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| US20060110428A1 (en) * | 2004-07-02 | 2006-05-25 | Eugene Dejuan | Methods and devices for the treatment of ocular conditions |
| JP4974903B2 (ja) * | 2005-02-09 | 2012-07-11 | 参天製薬株式会社 | 疾患または状態を処置するための液体処方物 |
| US20100016264A1 (en) * | 2007-12-05 | 2010-01-21 | Connor Charles G | Treatment for dry eye using testosterone and progestagen |
-
2006
- 2006-12-05 US US11/634,347 patent/US20080132475A1/en not_active Abandoned
-
2007
- 2007-12-05 BR BRPI0720172-9A patent/BRPI0720172A2/pt not_active IP Right Cessation
- 2007-12-05 MX MX2009005993A patent/MX2009005993A/es not_active Application Discontinuation
- 2007-12-05 EP EP07865242A patent/EP2101785A4/en not_active Withdrawn
- 2007-12-05 WO PCT/US2007/086517 patent/WO2008070728A2/en not_active Ceased
- 2007-12-05 EA EA200900663A patent/EA200900663A1/ru unknown
- 2007-12-05 EA EA200900662A patent/EA200900662A1/ru unknown
- 2007-12-05 WO PCT/US2007/086515 patent/WO2008070726A2/en not_active Ceased
- 2007-12-05 JP JP2009540451A patent/JP2010511729A/ja active Pending
- 2007-12-05 CA CA002671698A patent/CA2671698A1/en not_active Abandoned
- 2007-12-05 CN CN200780049245A patent/CN101636165A/zh active Pending
- 2007-12-05 CA CA002671769A patent/CA2671769A1/en not_active Abandoned
- 2007-12-05 JP JP2009540453A patent/JP2010511730A/ja active Pending
- 2007-12-05 KR KR1020097013349A patent/KR20090104814A/ko not_active Withdrawn
- 2007-12-05 EP EP07865244A patent/EP2124958A4/en not_active Withdrawn
- 2007-12-05 CN CN200780049235A patent/CN101636164A/zh active Pending
- 2007-12-05 KR KR1020097013348A patent/KR20090104813A/ko not_active Withdrawn
- 2007-12-05 BR BRPI0719918-0A2A patent/BRPI0719918A2/pt not_active IP Right Cessation
- 2007-12-05 MX MX2009005994A patent/MX2009005994A/es not_active Application Discontinuation
-
2009
- 2009-06-02 IL IL199094A patent/IL199094A0/en unknown
- 2009-07-03 AU AU2009202711A patent/AU2009202711A1/en not_active Abandoned
-
2013
- 2013-12-23 US US14/139,243 patent/US20140113889A1/en not_active Abandoned
-
2020
- 2020-02-18 US US16/793,581 patent/US20210008079A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010511730A5 (https=) | ||
| JP2010511729A5 (https=) | ||
| US20090010968A1 (en) | Spot-on formulation useful for cosmetology and dermatology | |
| JP6574191B2 (ja) | 浸透促進剤としてのカプリロイルアラニンエチルエステル | |
| DK1513514T3 (en) | Topical formulations of hydroxymatairesinol | |
| AU3708599A (en) | Use of pharmaceutical compositions capable of being gelled in periodontology | |
| FR2871698A1 (fr) | Composition sous forme de spray comprenant une association d'actifs pharmaceutiques et une phase huileuse | |
| MX2011007351A (es) | Composiciones esteroidales. | |
| JP2010511730A (ja) | テストステロンおよびプロゲスターゲンを用いたドライアイのための処置 | |
| JP2005513139A (ja) | 乾癬及び他の皮膚疾患の治療のための製薬組成物 | |
| KR20160084409A (ko) | 포스파티딜콜린을 포함하는 분무가능한 국소용 담체 및 조성물 | |
| JP4989119B2 (ja) | ベシクル系に好適な皮膚外用剤 | |
| RU2384337C2 (ru) | Композиция в форме аэрозоля, включающая комбинацию клобетазола пропионата и кальцитриола, спиртовую фазу и масляную фазу | |
| JP2008538753A5 (ja) | 骨の老化または骨粗しょう症の治療または予防用組成物 | |
| JP2788739B2 (ja) | にきびまたはアンドロゲン性脱毛の局所治療のためのエチステロンの使用 | |
| JPH07215848A (ja) | 皮膚外用剤及び皮膚化粧料 | |
| US20090075963A1 (en) | Transdermal hormone spray | |
| EP0223671B1 (fr) | Médicament à action synergétique anti-inflammatoire à base d'un corticostéroide et d'un beta-agoniste | |
| JP2000515120A (ja) | レチナールを含有する皮膚化粧組成物 | |
| JP6702783B2 (ja) | 皮膚浸透促進剤 | |
| JP2000351738A (ja) | 外用製剤 | |
| JP6396739B2 (ja) | 歯周病菌由来の酵素活性阻害剤 | |
| JP2001026551A (ja) | 薬物の有効性及び安定性を向上させる方法及び外用剤組成物 | |
| JP2009221144A (ja) | 表皮バリアー機能向上剤 | |
| US7758901B2 (en) | Compositions and methods for alleviating skin disorders |